Impact of antiangiogenic treatment on the erectile function in patients with advanced renal cell carcinoma.

We longitudinally assessed erectile function as well as the willingness to use pro‐erectile treatment in a cohort on AAT for advanced RCC. Thirty‐seven patients with advanced RCC completed the five‐item version of the International Index of Erectile Function (IIEF‐5) and other interview items before (T0) and 12 weeks into therapy (T12) with AAT. Patients were further asked if they were willing to use and pay out‐of‐pocket for on‐demand treatment with phosphodiesterase‐5‐inhibitors (PDE‐5i). Statistical analysis was performed using nonparametric hypothesis testing. The IIEF‐5 score at T12 was significantly decreased compared with T0 (p <.001). Subjective patient satisfaction regarding their sexual lives was associated with higher IIEF‐5 scores at both time points (p =.006 and p =.03, respectively). At T12, subjective sexual contentment showed a nonsignificant trend towards decline (p =.074). Patients who opted for medical treatment of ED showed significantly better IIEF‐5 scores at both time points compared with the rest of the cohort (p <.001 and p =.005, respectively). In summary, AAT seems to have a negative effect on erectile function in RCC patients, however, the role of psychosocial issues warrants further elucidation. Affected patients may benefit from a proactive approach promoting medical treatment of erectile dysfunction during AAT. [ABSTRACT FROM AUTHOR]